Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | Both sides next revision |
vaccine_innovation_prioritisation_strategy [2022/11/24 20:23]
liam [Microarray patches] | vaccine_innovation_prioritisation_strategy [2024/01/02 07:32] (current)
liam |
|---|
| ==== Microarray patches ==== | ==== Microarray patches ==== |
| |
| In May 2020, the VIPS Steering Committee selected and recommended three vaccine-related innovations to prioritize in order to increase uptake of [[vaccines]]. [[Microaray patches]] (MAPS) were identified as the highest priority (the other two were "heat-stable and controlled temperature chain qualified vaccines", and barcodes on primary packaging).((Vaccine Innovation Prioritisation Strategy (VIPS). (2021). //Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan// (p. 2). Gavi, the Vaccine Alliance. https://web.archive.org/web/20220806221838/https://www.gavi.org/sites/default/files/about/market-shaping/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf)) During the second half of 2020 and into 2021, the VIPS Working Group published a five-year plan to develop these MAPS. | In May 2020, the VIPS Steering Committee selected and recommended three vaccine-related innovations to prioritize in order to increase uptake of [[vaccines]]. [[Microarray patches]] (MAPS) were identified as the highest priority (the other two were "heat-stable and controlled temperature chain qualified vaccines", and barcodes on primary packaging).((Vaccine Innovation Prioritisation Strategy (VIPS). (2021). //Vaccine microarray patches (MAPs): public summary of the VIPS Alliance Action Plan// (p. 2). Gavi, the Vaccine Alliance. https://web.archive.org/web/20220806221838/https://www.gavi.org/sites/default/files/about/market-shaping/VIPS-Alliance-Action-Plan-for-MAPS_Public-Summary.pdf)) During the second half of 2020 and into 2021, the VIPS Working Group published a five-year plan to develop these MAPS. |
| |
| MAPS are small devices that "consist of an array of hundreds to thousands of micro-projections on a patch or backing. These micro-projections can be coated with, or are composed of, vaccine in a dry formulation." After being applied to the skin, the vaccine payload is delivered into the dermis and/or epidermis of the skin, which are rich in [[antigen]]-presenting cells. The two main types of MAPS being developed are solid-coated and dissolving. | MAPS are small devices that "consist of an array of hundreds to thousands of micro-projections on a patch or backing. These micro-projections can be coated with, or are composed of, vaccine in a dry formulation." After being applied to the skin, the vaccine payload is delivered into the dermis and/or epidermis of the skin, which are rich in [[antigen]]-presenting cells. The two main types of MAPS being developed are solid-coated and dissolving. |
